A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Determine The Efficacy and Safety of Buprenorphine (as NTC-510) in Subjects With Pain Following Surgical Extraction of 1 or 2 Third Molars.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Determine The Efficacy and Safety of Buprenorphine (as NTC-510) in Subjects With Pain Following Surgical Extraction of 1 or 2 Third Molars.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Buprenorphine/naloxone (Primary) ; Buprenorphine
  • Indications Dental pain
  • Focus Therapeutic Use
  • Sponsors Nanotherapeutics
  • Most Recent Events

    • 11 Apr 2016 Status changed from recruiting to discontinued because safety and efficacy after cohort 5 did not warrant further dose escalation
    • 04 Dec 2015 According to ClinicalTrials.gov record, the treatment table has been amended due to the addition of NTC-510A (Buprenorphine alone) and hence the patients no has also been increased.
    • 04 Dec 2015 Planned number of patients changed from 24 to 66, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top